Search

Your search keyword '"Morton, David A.V."' showing total 164 results
Start Over Author "Morton, David A.V."
164 results on '"Morton, David A.V."'

9. Developing Dry Powder Inhaler Formulations.

Author

Morton, David A.V. and Barling, David

Subjects
*INHALERS, *POWDERS, *CONSUMER preferences, *REFERENCE sources, *NEW product development
Abstract

This section aims to provide a concise and contemporary technical perspective and reference resource covering dry powder inhaler (DPI) formulations. While DPI products are currently the leading inhaled products in terms of sales value, a number of confounding perspectives are presented to illustrate why they are considered surprisingly, and often frustratingly, poorly understood on a fundamental scientific level, and most challenging to design from first principles. At the core of this issue is the immense complexity of fine cohesive powder systems. This review emphasizes that the difficulty of successful DPI product development should not be underestimated and is best achieved with a well-coordinated team who respect the challenges and who work in parallel on device and formulation and with an appreciation of the handling environment faced by the patient. The general different DPI formulation types, which have evolved to address the challenges of aerosolizing fine cohesive drug-containing particles to create consistent and effective DPI products, are described. This section reviews the range of particle engineering processes that may produce micron-sized drug-containing particles and their subsequent assembly as either carrier-based or carrier-free compositions. The creation of such formulations is then discussed in the context of the material, bulk, interfacial and ultimately drug-delivery properties that are considered to affect formulation performance. A brief conclusion then considers the future DPI product choices, notably the issue of technology versus affordability in the evolving inhaler market. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries

Author

Prankerd, Richard J., Nguyen, Tri-Hung, Ibrahim, Jibriil P., Bischof, Robert J., Nassta, Gemma C., Olerile, Livesey D., Russell, Adrian S., Meiser, Felix, Parkington, Helena C., Coleman, Harold A., Morton, David A.V., McIntosh, Michelle P., Prankerd, Richard J., Nguyen, Tri-Hung, Ibrahim, Jibriil P., Bischof, Robert J., Nassta, Gemma C., Olerile, Livesey D., Russell, Adrian S., Meiser, Felix, Parkington, Helena C., Coleman, Harold A., Morton, David A.V., and McIntosh, Michelle P.

Abstract

Oxytocin is recommended by the World Health Organisation as the most effective uterotonic for the prevention and treatment of postpartum haemorrhage. The requirement for parenteral administration by trained healthcare providers and the need for the drug solution to be maintained under cold-chain storage limit the use of oxytocin in the developing world. In this study, a spray-dried ultrafine formulation of oxytocin was developed with an optimal particle size diameter (1-5 μm) to facilitate aerosolised delivery via the lungs. A powder formulation of oxytocin, using mannitol, glycine and leucine as carriers, was prepared with a volume-based median particle diameter of 1.9 μm. Oxytocin content in the formulation was assayed using high-performance liquid chromatography-mass spectroscopy and was found to be unchanged after spray-drying. Ex vivo contractility studies utilising human and ovine uterine tissue indicated no difference in the bioactivity of oxytocin before and after spray-drying. Uterine electromyographic (EMG) activity in postpartum ewes following pulmonary (in vivo) administration of oxytocin closely mimicked that observed immediately postpartum (0-12 h following normal vaginal delivery of the lamb). In comparison to the intramuscular injection, pulmonary administration of an oxytocin dry powder formulation to postpartum ewes resulted in generally similar EMG responses, however a more rapid onset of uterine EMG activity was observed following pulmonary administration (129 ± 18 s) than intramuscular injection (275 ± 22 s). This is the first study to demonstrate the potential for oxytocin to elicit uterine activity after systemic absorption as an aerosolised powder from the lungs. Aerosolised oxytocin has the potential to provide a stable and easy to administer delivery system for effective prevention and treatment of postpartum haemorrhage in resource-poor settings in the developing world. © 2013 Prankerd et al.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results